Single Dose of zilebesiran Lowers Blood Pressure for Six Months: Phase 2 KARDIA study Dr. Kamal Kant Kohli19 Nov 2024 9:30 AM ISTA groundbreaking study presented at the American Heart Association's Scientific Sessions 2023 unveils promising results for a novel hypertension drug,...
Hypertension: KARDIA-1 trial suggests zilebesiran potentially effective antihypertensive with quarterly or biannual dosing Medha Baranwal21 Feb 2024 7:15 PM ISTUSA: RNA interference with zilebesiran can significantly lower blood pressure for up to 6 months, indicating potential for use as an effective...
Single injection of zilebesiran effective in lowering BP for six months in hypertension patients: KARDIA-1 trial Medha Baranwal29 Nov 2023 10:00 AM ISTUSA: New data from the KARDIA-1 Phase 2 study showed that a single injection of the investigational antihypertensive agent zilebesiran was effective...
Investigational zilebesiran tied to potent dose-dependent reduction of BP: Topline phase 2 data Dr. Kamal Kant Kohli14 Sept 2023 10:00 AM ISTUSA: In adults with hypertension, an investigational RNA interference agent targeting angiotensin, was shown to be associated with a clinically...
Phase 2 study of Zilebesiran met primary endpoint: Roche,Alnylam Ruchika Sharma9 Sept 2023 12:38 PM ISTBasel: Roche and Alnylam have announced that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed...
Roche, Alnylam collaborate for hypertension therapy Ruchika Sharma24 July 2023 12:29 PM ISTUnder the terms of the agreement, Alnylam will receive an upfront payment of USD 310m and is eligible to receive development, regulatory and...
Investigational RNA interference therapeutic agent Zilebesiran effective for treatment of hypertension Niveditha Subramani22 July 2023 11:45 AM ISTAngiotensinogen has previously been assumed to be a passive substrate, however recent studies reveal an inherent conformational mechanism that is...
